HDAC9 and diffuse large B-cell lymphoma: To investigate the in vitro inhibitory activity of a novel class I and IIb selective histone deacetylase(HDAC)inhibitor, purinostat mesylate(PM), in diffuse large B-cell lymphoma and its mechanism.